Det har gennem et unikt internationalt samarbejde været muligt at gennemføre to store randomiserede kliniske studier for åben versus laparoskopisk kirurgi for henholdsvis colon- og rectumcancer. Man kunne dog ikke gennemføre studierne blindede. Flere afdelinger inkluderede relativt få patienter, og nogle af de opererende kirurger har formentlig befundet sig på deres indlæringskurve for laparoskopisk kirurgi. Det betyder, at der har været en række muligheder for bias undervejs.

SP-D opreguleres ved inflammatorisk aktivitet hos patienter med inflammatorisk tarmsygdom, formentligt for kompensatorisk at kontrollere og dæmpe inflammationen. SP-D påvirker ikke direkte DSS-induceret inflammation hos mus - muligvis på grund af meget lavt SP-D-udtryk i musenes tarm. Fremtidige studier bør yderligere afklare effekten af SP-D på inflammation i den humane tarm.

VARSITY-studien

Studier som sammenligner biologiske legemidler er viktige og har lenge vært etterspurt i det kliniske miljøet. Resultater fra slike studier bidrar til å bedre grunnlaget for valg av behandling for IBD-gruppen. Vi har nå første gang en direkte sammenligning mellom to biologiske legemidler med to ulike virkemekanismer – vedolizumab og adalimumab. Resultatene er til fordel for vedolizumab, for effekt så vel som sikkerhet ved ulcerøs kolitt.

MEST SETE MEDtalks

ECCO 2019: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease   Se hele webinar

ECCO 2019: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/ecco-2019-prevalence-and-healthcare-costs-of-perianal-fistulas-in-crohns-disease/'>Se hele webinar
Prevalence and healthcare costs of perianal fistulas in Crohn’s disease

ECCO 2019: Kræftrisiko ved IBD opstået i barndommen

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: Kræftrisiko ved IBD opstået i barndommen&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/ecco-2019-ibd-cancer-and-serious-infections-in-europe-i-care-study-2/'>Se hele webinar
Kræftrisiko ved IBD opstået i barndommen

ECCO 2019: Treatment of IBD with thiopurine and allopurinol vs thiopurine monotherapy

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: Treatment of IBD with thiopurine and allopurinol vs thiopurine monotherapy&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/ecco-uc-and-cd-increased-the-risk-of-type-2-diabetes-2-3-2/'>Se hele webinar
Treatment of IBD with thiopurine and allopurinol vs thiopurine monotherapy

ECCO 2019: Vedolizumab vs adalimumab in patients with active ulcerative colitis

<script src="https://fast.wistia.com/embed/medias/b5rwewng4t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b5rwewng4t seo=false videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/b5rwewng4t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ECCO 2019: Vedolizumab vs adalimumab in patients with active ulcerative colitis&nbsp;&nbsp;&nbsp;<a href='https://bestprac.dk/webinar/ecco-2019-vedolizumab-vs-adalimumab-in-patients-with-active-ulcerative-colitis/'>Se hele webinar
Vedolizumab vs adalimumab in patients with active ulcerative colitis

Sexual Dysfunction and Inflammatory Bowel Disease

Sexual dysfunction is more common among men and women with Inflammatory Bowel Disease (IBD) than in the background population. Previous studies have shown that about 40-60% of women with IBD and up to 44% of men with IBD report sexual dysfunction.1,2 A recent meta-analysis by Zhao et al. of eight studies with control groups found that IBD was significantly associated with an elevated risk of sexual dysfunction in men (relative risk [RR]: 1.41; 95% CI: 1.09–1.8) and women (RR: 1.76; 95% CI: 1.28–2.42).3  Inflammatory bowel disease patients with a relatively young age (male: <50 years; female: <40 years) had significantly increased odds of sexual dysfunction compared with controls. Six of the studies in this meta-analysis used the “gold standard” Female Sexual Function Index (FSFI)4 and International Index of Erectile Function (IIEF)5 for comparison of sexual function in patients with IBD to that of individuals in the general population. The other…

September 20-21, 2019  Comwell Kolding, Kolding, Denmark   Dear colleagues, Center for Pancreatic Diseases (Aalborg University Hospital) and Odense Pancreas Center (OPAC, Odense University Hospital) are happy to announce the First Scandinavian Baltic Pancreas Symposium. The symposium will cover several aspects of benign and malignant pancreatic diseases, but with special focus on genetics in Chronic Pancreatitis, Hypoglycemia and Pancreatic Cancer.  The symposium includes State-of-the-Art Lectures, Meet the Experts and Breakout Sessions as well as Poster Exhibition and Awards (Program) We hope that you will join the symposium, and that you may consider submitting an abstract for the Poster Exhibition. An expert committee will evaluate all posters, and the three best posters will be presented orally and awarded on Friday evening.  More information and registration are available on www.OPAC.nu    Looking forward to seeing you at the symposium, 

ECCO-konferencen i København

6.-9. marts blev der afholdt ECCO-kongres i Bella Centeret i København. Med 7960 registrerede deltagere var det den hidtil største kongres om inflammatoriske tarmsygdomme. ECCO er en europæisk faglig organisation med betydelig impact på fagområdet. Selve kongressen har ud over det lægefaglige program også selvstændige programmer for blandt andet IBD-interesserede sygeplejersker og diætister. Der er ”IBD Intensive Advanced Course” og en række uddannelsestilbud om blandt andet ultralydsundersøgelse ved IBD. ECCO udgiver også guidelines og arbejder for at fremme forskning: SciCom og UR-CARE. ECCO har udviklet sig fra at være en europæisk kongres til nu at have deltagere fra hele verden. Det er derfor naturligvis en ære, når ECCO-organisationen vælger København som kongresby. Vi vil vælge at opfatte det som en anerkendelse af den IBD-forskning af høj kvalitet, der er blevet præsteret i Danmark og de skandinaviske lande. Vi hilser dette meget velkomment og håber, at det vil anspore til yderligere…

#Seneste udgivelse

Gastroenterologi

Nr. 7 • juni 2019
3. Årgang
  • IBD
  • Tarmbakteriernes betydning
  • Ny viden om tuftceller

ECCO 2019

Vi anbefaler

Vi anbefaler

Effektvurdering ved opstart

Speaker: Brian Bressler

Spilletid: 3:53

Optimering af behandlingen af IBD

Speaker: Brian Bressler

Spilletid: 10:33

#

Gastroenterologi

Christian Lodberg Hvas

Christian Lodberg Hvas
overlæge, ph.d., klinisk lektor

Ebbe Langholz

Ebbe Langholz
overlæge, dr.med.

Lone Larsen

Lone Larsen
overlæge

Mette Julsgaard

Mette Julsgaard
læge, ph.d.